CN114939105A

CN114939105A - Composite collagen hydrogel and preparation method and application thereof

Info

Publication number: CN114939105A
Application number: CN202210676381.XA
Authority: CN
Inventors: 王玠; 许菲; 曹俊; 戴洋; 邢云天
Original assignee: Jiangsu Institute of Parasitic Diseases
Current assignee: Jiangsu Institute of Parasitic Diseases
Priority date: 2022-06-15
Filing date: 2022-06-15
Publication date: 2022-08-26
Anticipated expiration: 2042-06-15
Also published as: CN114939105B

Abstract

The invention discloses a composite collagen hydrogel and a preparation method and application thereof, the composite collagen hydrogel comprises an active component and a gelling component, and the gelling component is converted into gel by an oxidant to form the composite collagen hydrogel; the active component comprises niclosamide or praziquantel, before the active component is converted into gel, the mass volume concentration of recombinant collagen in the gelling component is 20-100 g/L, the mass volume concentration of gelatin is 10-100 g/L, and the amino acid sequence of the recombinant collagen is SEQ ID No. 1. According to the invention, the recombinant collagen and the natural collagen gelatin are synthesized into the double-component composite collagen hydrogel, so that the hydrogel has better mechanical properties, drug-bearing release aperture and biocompatibility, and the drug slow-release and cercaria infection resisting effects are improved; the hydrogel greatly improves the egg reduction rate and the insect reduction rate of schistosomiasis, and provides a new idea for developing a novel anti-cercaria infection protective agent and injecting a schistosomiasis treatment drug.

Description

Composite collagen hydrogel and preparation method and application thereof

Technical Field

The invention belongs to the technical field of medicines. More particularly, relates to a composite collagen hydrogel and a preparation method and application thereof.

Background

Schistosomiasis is a zoonosis caused by schistosome infection. This disease poses serious harm to human health and socioeconomic performance in epidemic areas. To date, more than 2.5 million people and nearly 8 million people worldwide are at risk for schistosomiasis infection. The life history of schistosome is complex, and the aquatic cercaria stage is the only infection stage. The chemical molluscicide commonly used for field molluscacide at present is niclosamide, which is also a recommended chemical molluscacide by the world health organization, and has strong killing effect on schistosoma japonicum cercaria and miracidium. However, niclosamide has a short half-life and is easily degraded under light; can be quickly diluted to lose the insecticidal effect in the field water body application, and can have toxicity to non-target aquatic animals such as fish and the like in the water body to cause environmental pollution, so the field use effect is not ideal. In addition, the first-line drug for preventing and treating schistosomiasis of human bodies and animals at present is praziquantel which has better treatment effect, but the first-line drug cannot prevent schistosomiasis for a long time due to fast metabolism, so that the development of a new anti-schistosomiasis drug which can play a role in preventing and treating schistosomiasis for a long time is urgently needed.

Long-acting preparations for injection are receiving more and more attention because of their simple preparation, accurate dosage, convenient administration and little influence from external factors. A hydrogel is a soft 3D structural polymer material that is a three-dimensional cross-linked network of hydrophilic polymeric materials, the specific structure and subsequent swelling properties enabling it to absorb large amounts of liquid between the polymer chains. Therefore, it can promote the release of drug molecules encapsulated in hydrogel by the change of environment by encapsulating the target drug in the hydrogel matrix. In recent years, functional hydrogels have become advanced materials for new applications ranging from drug delivery, drug-loaded treatment of disease, to wound dressing healing, tissue engineering, etc. In addition, the hydrogel material and the drug-loaded hydrogel have good mechanical strength and high stability, larger drug loading capacity, longer release time and the like and are used in the field of anti-parasites, for example, a supramolecular hydrogel slow-release drug system based on alanine derivatives, melamine and riboflavin is adopted to construct a schistosoma japonicum cercaria slow-release type hydrogel medicament; the injectable long-acting preparation is prepared by injectable thermosensitive poly (lactide-glycolide-p-dioxane ketone) -polyethylene glycol block copolymer hydrogel. However, the hydrogels used at present are all non-natural hydrogels or ester-alcohol copolymers, and these supramolecular non-natural hydrogels have potential safety hazards in animals and human bodies, so that they cannot be used clinically.

The collagen is the most abundant protein in the body of the mammal and accounts for 25-30% of the total amount of the protein. The natural biodegradable properties of collagen make it well suited for development as a biomedical material to promote cell growth and metabolism, and can be compounded with other natural polymers, inorganic or organic materials, and biomaterials. However, natural animal-derived collagen is often inconsistent in purity and quality and susceptible to contamination by various diseases carried by animals. Although the purity of recombinant proteins such as streptococcal collagen is high, the recombinant proteins cannot be assembled into stable three-dimensional bioactive hydrogel due to low gel strength, and the use of exogenous crosslinking agents has the problem of residual crosslinking agents, so that the application is limited. There is a need to develop a collagen with high purity, good biocompatibility, biodegradability and molecular designability, no animal-derived disease contamination, and stronger gel strength.

Gelatin (gelatin) is one of polymers derived from natural hydrogel, is a product obtained after collagen hydrolysis, contains 18 amino acids and 90% of collagen, can swell in water at 35-40 ℃, is safe and non-toxic, can form thermo-reversible gel, is an ideal natural collagen sustained release agent, and has the defects of low gel hardness, low mechanical property, small protein pore size and poor drug sustained release effect.

Disclosure of Invention

The invention provides a composite collagen hydrogel for overcoming the defects of the prior art. The composite collagen hydrogel has high purity, good biocompatibility, biodegradability, safety, no toxicity and good drug release effect.

The invention aims to provide a composite collagen hydrogel.

Another object of the present invention is to provide a method for preparing the composite collagen hydrogel

The invention also aims to provide the application of the composite collagen hydrogel in preparing medicaments for preventing and/or preventing schistosomiasis infection.

In order to realize the purpose, the following technical scheme is adopted:

a composite collagen hydrogel comprising an active component and a gel-forming component, said composite collagen hydrogel being formed by converting said gel-forming component into a gel by an oxidizing agent; the active component comprises niclosamide or praziquantel, before the active component is converted into gel, the mass volume concentration of recombinant collagen in the gelling component is 20-100 g/L, the mass volume concentration of gelatin is 10-100 g/L, and the amino acid sequence of the recombinant collagen is SEQ ID No. 1.

According to the invention, the recombinant collagen and the natural collagen gelatin are synthesized into the double-component recombinant collagen hydrogel, so that the recombinant collagen and the natural collagen are compatible, and a structure more suitable for cercaria-resistant medicines can be obtained by accidental discovery, so that the hydrogel has better mechanical properties and medicine bearing and release pore diameters, and the medicine slow-release and cercaria-resistant infection effects are improved.

Further, the active component is niclosamide, and the mass volume concentration of the active component is 0.1-10 mg/L.

Preferably, the active component is niclosamide, and the mass volume concentration of the active component is 1 mg/L.

Furthermore, the active component is praziquantel, and the mass volume concentration of the active component is 10-200 mg/L.

Preferably, the active component is praziquantel, and the mass volume concentration of the active component is 150 mg/L.

Further, the oxidant is H ₂ O ₂ 。

Furthermore, the oxidant can be used for oxidizing and inducing the formation of intermolecular disulfide bonds among cysteines in the recombinant collagen to promote gelation.

Preferably, the oxidizing agent is also peracetic acid, sodium dichromate, chromic acid, nitric acid.

The scheme also requests to protect the preparation method of the composite collagen hydrogel, and the preparation method comprises the following steps:

s1, mixing a recombinant collagen solution and a gelatin solution, and then adding an active component to form a recombinant collagen-gelatin-active component-water mixed solution;

s2, adding an oxidant into the recombinant collagen-gelatin-active component-water mixed solution, cooling and standing for reaction to obtain the composite collagen hydrogel.

Further, in the S1, the temperature of the mixed solution system is 40-90 ℃.

Further, in the step S2, the mixture is cooled and placed still for reaction for at least 7 days at the temperature of 0-8 ℃.

Because the recombinant collagen is 33kda macromolecules, a certain time is needed in the process of oxidizing by cysteine and forming a network structure, the gelling time is generally more than 7 days, and the gelling speed can be increased by cooling at the temperature of 0-8 ℃.

Preferably, the mixture is cooled and left at rest for 7 days at 4 ℃.

Further, the oxidant in the S2 is H with the mass volume concentration of 0.5-5 g/L ₂ O ₂ 。

Preferably, the oxidant in the S2 is H with the mass volume concentration of 1g/L ₂ O ₂ 。

The scheme also requests the application of the composite collagen hydrogel in the preparation of the medicine for preventing and/or preventing schistosomiasis infection.

Further, the medicament is in a form of smearing preparation or injection.

Compared with the prior art, the invention has the following beneficial effects:

the composite collagen hydrogel has better mechanical property and drug bearing and releasing aperture, improves the mechanical property of the hydrogel and drug slow release, the releasing time can reach 20 days, and the releasing rate is kept at 80 percent; the composite collagen hydrogel greatly improves the egg reduction rate and the insect reduction rate of schistosomiasis, when the active component is niclosamide, the egg reduction rate and the insect reduction rate can respectively reach 85.25 percent and 87.57 percent, the composite collagen hydrogel can also be used as a praziquantel drug injection slow-release agent, has good biocompatibility, and the egg reduction rate and the insect reduction rate can respectively reach 89.69 percent and 92.11 percent by infecting mice with schistosomiasis through subcutaneous injection of the praziquantel collagen bi-component hydrogel. Lays a foundation for the development of a novel protective agent for resisting cercaria infection based on the composite collagen hydrogel, and provides a new idea for injection treatment of schistosomiasis drugs.

Drawings

Figure 1 SEM images with the addition of the two components (gelatin + protein) and without the addition of the oxidizing agent.

FIG. 2 is a standard curve for niclosamide concentration measurement.

Figure 3 cumulative release efficiency of niclosamide in hydrogels.

Detailed Description

The invention is further described with reference to the drawings and the following detailed description, which are not intended to limit the invention in any way. The reagents, methods and apparatus employed in the present invention are conventional in the art, unless otherwise indicated.

Unless otherwise indicated, reagents and materials used in the following examples are commercially available.

Description of the experimental materials: the experimental schistosoma japonicum cercaria escapes from the autotrophic positive oncomelania (oncomelania infected by schistosoma japonicum) of the schistosomiasis prevention and treatment research institute of Jiangsu province, and is incubated in the key laboratory of the schistosomiasis prevention and treatment research institute of Jiangsu province. Balb/c mice were purchased from Yangzhou university and were male mice weighing 20. + -.3 g. The animals were kept for 3d in a Specific Pathogen Free (SPF) experimental environment during which they were fed 1 time per day. The feeding is stopped 24 hours before the experiment is started, and the feces and food residues are removed in time. The room temperature was controlled at 27 ℃ throughout the experiment, and the test water was purified water.

The recombinant collagen is named S-VCL-S3, is derived from streptococcus collagen Scl2(S. pyrogenes Scl2), and comprises a spherical domain V and a CL domain of a triple-helical domain Gly-Xaa-Yaa. Introducing cysteines at the N-and C-termini of the CL domains of the globular domain V and the triple-helical domain Gly-Xaa-Yaa, and replacing amino acids located in the middle of the CL domains, 1/3 and 2/3 with cysteines to achieve oxidative crosslinking; the S-VCL-S3 protein sequence is as follows: as shown in SEQ ID No.1, the S-VCL-S3 protein has better gel effect compared with other streptococcus collagen-like proteins, so that the S-VCL-S3 protein is used as a recombinant protein in subsequent experiments.

In the examples, the recombinant collagens used are all recombinant collagen S-VCL-S3.

Example 1

The preparation method of the composite collagen hydrogel comprises the following steps:

s1, mixing a recombinant collagen solution and a gelatin solution, adding an active component, namely niclosamide, and keeping the temperature of a mixed solution system at 40 ℃ to form a recombinant collagen-gelatin-niclosamide-water mixed solution; in the mixed solution, the gelling components are recombinant collagen and gelatin, the mass volume concentration of the recombinant collagen in the mixed solution is 40g/L, the mass volume concentration of the gelatin in the mixed solution is 15g/L, the active component is niclosamide, and the mass volume concentration of the niclosamide in the mixed solution is 1 mg/L.

S2, adding 20mg/L oxidant H into the recombinant collagen-gelatin-niclosamide-water mixed solution ₂ O ₂ Oxidizing the mixture with hydrogen ₂ O ₂ The final mass volume concentration was 1mg/L, and the mixture was left at 4 ℃ for at least 7 days, cooled and left to stand to prepare example 1.

Example 2

s1, mixing a recombinant collagen solution and a gelatin solution, adding an active component, namely niclosamide, and keeping the temperature of a mixed solution system at 60 ℃ to form a recombinant collagen-gelatin-niclosamide-water mixed solution; in the mixed solution, the gelling components are recombinant collagen and gelatin, the mass volume concentration of the recombinant collagen in the mixed solution is 20g/L, the mass volume concentration of the gelatin in the mixed solution is 10g/L, the active component is niclosamide, and the mass volume concentration of the niclosamide in the mixed solution is 1 mg/L.

S2, adding 20mg/L oxidant H into the recombinant collagen-gelatin-niclosamide-water mixed solution ₂ O ₂ Allowing it to oxidize H ₂ O ₂ The final mass volume concentration was 0.5mg/L, and the mixture was left at 0 ℃ for at least 7 days, cooled and left to stand to prepare example 2.

Example 3

s1, mixing a recombinant collagen solution and a gelatin solution, adding an active component, namely niclosamide, and keeping the temperature of a mixed solution system at 90 ℃ to form a recombinant collagen-gelatin-niclosamide-water mixed solution; in the mixed solution, the gelling components are recombinant collagen and gelatin, the mass volume concentration of the recombinant collagen in the mixed solution is 80g/L, the mass volume concentration of the gelatin in the mixed solution is 50g/L, the active component is niclosamide, and the mass volume concentration of the niclosamide in the mixed solution is 1 mg/L.

S2, adding 20mg/L oxidant H into the recombinant collagen-gelatin-niclosamide-water mixed solution ₂ O ₂ Oxidizing the mixture with hydrogen ₂ O ₂ The final concentration by mass/volume was 5mg/L, and the mixture was left at 8 ℃ for at least 7 days, cooled and left to stand to prepare example 3.

Examples 4 to 6

Examples 4 to 6 were prepared according to the preparation method of example 1 with the composition of each component shown in table 1.

Example 7

s1, mixing a recombinant collagen solution and a gelatin solution, adding an active component, namely praziquantel, and keeping the temperature of a mixed solution system at 40 ℃ to form a recombinant collagen-gelatin-praziquantel-water mixed solution; in the mixed solution, the gelling components are recombinant collagen and gelatin, the mass volume concentration of the recombinant collagen in the mixed solution is 40g/L, the mass volume concentration of the gelatin in the mixed solution is 15g/L, the active component is praziquantel, and the mass volume concentration of the praziquantel in the mixed solution is 150 mg/L.

S2, adding an oxidant H with the concentration of 20mg/L into the recombinant collagen-gelatin-praziquantel-water mixed solution ₂ O ₂ Allowing it to oxidize H ₂ O ₂ Example 7 was prepared by standing at 4 ℃ for at least 7 days with a final mass volume concentration of 1mg/L, cooling and standing.

Examples 8 to 9

Examples 8 to 9 were prepared according to the composition of the components in table 1 by referring to the preparation method of example 7.

TABLE 1 compositions and amounts of examples 1-9

Comparative example 1

The preparation method and the steps are the same as those of the example 1, except that gelatin is not added, namely, the gelatin-forming component is only recombinant collagen without gelatin, and the comparative example 1 is prepared.

Comparative example 2

The preparation method and steps are the same as those of example 1, except that recombinant collagen is not added, that is, the gelatin component is gelatin only and no recombinant collagen is added, and comparative example 2 is prepared.

Comparative example 3

The preparation method and the steps are the same as those of the example 1, except that no oxidant H is added ₂ O ₂ Comparative example 3 was prepared.

Comparative example 4

The preparation method and the steps are the same as the example 1, except that gelatin is not added, namely, the gelatin-forming component is only recombined collagen without gelatin, and oxidant H is not added ₂ O ₂ Comparative example 4 was prepared.

Comparative examples 5 to 17

Comparative examples 5 to 13 were obtained according to the following composition of table 2 with reference to the preparation method of comparative example 1, and comparative examples 14 to 17 with reference to the preparation method of example 7.

TABLE 2 compositions and amounts of comparative examples 1 to 17

Experimental example 1 composite collagen hydrogel formation verification experiment

1. Experimental methods

To verify the formation of the present gel, the above examples 1 to 9 and comparative examples 1 to 17 of the samples to be gel prepared were allowed to stand by cooling, and then the container in which the samples to be gel prepared were placed was inverted, and if the polymer molecules were crosslinked to form a hydrogel, their fluidity was limited and remained at the bottom of the container. Otherwise, the gel flows and the hardness of the gel is checked by shaking the container, and if the gel hardness is low, the gel will continuously shake by shaking the container, and if the gel does not continuously shake by shaking, the gel with high hardness is obtained.

2. Results of the experiment

By observing the gel forming property and the gel hardness of each sample, wherein whether the gel can be formed is shown in the table, 3, the gel can be formed in the examples 1 to 9, and the gel cannot be formed in the comparative examples 1, 3, 4, 6 to 9, 15 and 17; in terms of gel hardness, the sample added with the recombinant collagen and the gelatin double components has higher gel hardness than the sample of single-component gelatin.

The result shows that the single-component recombinant collagen is not easy to form gel; the single component gelatin can form a gel, and the recombinant collagen can form a harder gel after being mixed with the gelatin. Different gel samples are placed in a constant temperature box at 40 ℃ and are kept as solutions, and the gel can be formed after cooling. The results demonstrate that the two-component gel works best. Gelatin forms a gel at room temperature, dissolves to a solution at a temperature 40 ℃ above the Tm, and has gelling reversibility.

TABLE 3 gelling cases for examples 1 to 9 and comparative examples 1 to 17

Experimental example 2 composite collagen hydrogel scanning Electron microscope assay

1. Experimental method

The samples prepared in example 1, comparative example 1, and comparative examples 3 and 4 were taken and the hydrogels were lyophilized using a FreeZone Plus6L cascade console freeze drying System (Labconco, Kansas City, Mo., USA). The lyophilized hydrogel was sputter coated with a thin layer of palladium/gold alloy to improve the surface conductivity of the SEM. Images of the morphology and microstructure of the hydrogel were obtained using a hitachi SU1510 SEM (tokyo, japan) at an acceleration voltage of 5 kV.

2. Results of the experiment

The influence of the gel-forming component and the oxidant on the microstructure of the composite collagen hydrogel is verified through the shape and microstructure image of the hydrogel, and experimental results show that the recombinant collagen S-VCL-S3 is freeze-dried without H ₂ O ₂ In the case of (2), a loose pore structure is formed as shown in FIG. 1(1), and H is added ₂ O ₂ Thereafter, S-VCL-S3 forms a more dense pore structure, as shown in FIGS. 1(2) and 1(3), with no H added ₂ O ₂ Compared with the S-VCL-S3 protein, H is added ₂ O ₂ The microstructure of the S-VCL-S3 hydrogel is more rigid and the pores are more obvious. In addition, as shown in FIGS. 1(4) to (6), the composite collagen hydrogel prepared from the recombinant collagen S-VCL-S3 and gelatin as the gel-forming component can form a more rigid and dense pore structure.

Experimental example 3 hydrogel-coated drug and Release

1. Purpose of experiment

In order to observe the sustained release capacity of the collagen hydrogel to the drugs, the single-component collagen hydrogel in comparative example 1, the single-component gelatin hydrogel in comparative example 2 and the double-component gelatin hydrogel in example 1 are wrapped by 1mg/L niclosamide, and the influence of the hydrogels with 3 concentrations on the release rate of the niclosamide is observed.

2. Experimental methods

For the single-component collagen group, 100 μ L of each of the samples of example 1 (two-component), comparative example 1 (single-component protein), and comparative example 2 (single-component gelatin) was added to a 96-well plate; addition of ddH ₂ O (200. mu.L) into the wells, thereby releasing niclosamide. Detecting the content of niclosamide in the aqueous solution by High Performance Liquid Chromatography (HPLC) at 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 72, 96, 144, 168, 192, 216, 240 and 480 hours, respectively, collecting 10 μ L of the solution at each time point, and supplementing equal amount of ddH ₂ And O. Using ddH to test solution ₂ Diluting O to a ratio of 1:50, and performing high performance liquid chromatography with ZORBAX SB-C18(4.6mm × 250mm particle size 5 μm); the mobile phase is methanol: water 90: 10(V/V), pH 4, filtered through a 0.22 μm pore size filter; column temperature: 25 ℃ (room temperature); the detection wavelength is 330 nm; flow rate: 1.0 mL/min; sample introduction volume: 5 μ L.

Before measurement, a standard curve of niclosamide concentration detection is drawn according to the prepared niclosamide standard solution, and the standard deviation is measured. The specific operation is as follows: and preparing a 60mg/L niclosamide methanol solution, diluting the solution into standard solutions of 30mg/L, 6mg/L, 3mg/L, 0.6mg/L and 0.3mg/L respectively, and determining according to chromatographic conditions to obtain a standard curve for detecting the concentration of niclosamide. The peak areas of the chromatograms were linearly regressed with concentration. The standard curve is shown in figure 2, and the regression equation is that y is 19.668x-3.7227，R ² The linear relationship is good at 0.9998. Standard solutions of 60, 6 and 0.6mg/L were prepared, and measured 7 times respectively to calculate the precision. 60. The Relative Standard Deviations (RSD) of 6 and 0.6mg/L were 0.68%, 0.62% and 2.13%, respectively.

3. Results of the experiment

As shown in fig. 3, the cumulative release efficiency of niclosamide in the hydrogel was measured. 5.39 +/-0.24%, 10.45 +/-0.18% and 6.45 +/-0.18% niclosamide are respectively released from the gelatin group, the collagen group and the two-component gel group in the hydrogel for 30 min; after 72h, 24.94 + -0.78%, 68.45 + -1.20% and 36.45 + -1.20% of niclosamide were released from the gelatin group, the collagen group and the two-component gel group, respectively. The gelatin group, the collagen group and the two-component gel group can respectively release 43.78 +/-2.67 percent, 76.14 +/-1.25 percent and 51.96 +/-1.26 percent of niclosamide within 240 hours. The 480 hour gelatin group, collagen group and two-component gel group were able to release 43.59 + -1.14%, 77.67 + -1.11% and 51.24 + -1.11% niclosamide, respectively. The results show that the three hydrogels can gradually release molecules wrapped in the gelatin into the solution, and all have certain drug slow-release capacity, thereby meeting the drug slow-release requirement of the biological material. In addition, the release rates of the three hydrogels are different, the collagen group is obviously higher than the hydrogel of the two components and the gelatin group in the aspect of the early drug release rate, and about 70 percent of niclosamide can be released in 3 days. However, the retention time of the medicine in the bi-component hydrogel and the single-component gelatin group is longer than that of the collagen hydrogel, and compared with the bi-component hydrogel of the S-VCL-S3 and the gelatin and the collagen hydrogel, the bi-component hydrogel can form more stable hydrogel, the aqueous solution of the gel surface is not easy to dilute, the medicine release is slower, the retention time in the gel can reach 20 days, and the application prospect is better.

Experimental example 4 cercaria Release and collagen hydrogel toxicity test in vitro

1. Experimental methods

Samples of comparative example 5, example 1 and examples 4 to 6 were obtained by referring to the preparation method of example 1, and samples of comparative example 1 and comparative examples 6 to 9 were used as niclosamide two-component gel test sets (two-component gel test sets) having final concentrations of niclosamide of 0mg/L, 0.05mg/L, 0.1mg/L, 0.5mg/L and 1mg/L, respectively, as niclosamide one-component collagen hydrogel test sets (collagen sets) having final concentrations of niclosamide of 0mg/L, 0.05mg/L, 0.1mg/L, 0.5mg/L and 1mg/L, and comparative examples 2 and 10 to 13 were used as niclosamide one-component gelatin hydrogel test sets (gelatin sets) having final concentrations of niclosamide of 0mg/L, 0.05mg/L, 0.1mg/L, 0.5mg/L and 1mg/L, respectively. The above hydrogel was added to a 96-well plate, and PBS (200 μ l) was added to the hydrogel surface per well, thereby releasing niclosamide. 6h before the experiment, the temperature is 25 ℃, and the positive oncomelania is placed into the dechlorinated water to release cercaria under the condition of fixing a fluorescent lamp light source. 10 cercaria were placed in each PBS well and tested for mortality at 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 72 hours.

2. Results of the experiment

The results are shown in Table 4, and the results show that the niclosamide hydrogel with the concentration of 1mg/L, 0.5mg/L, 0.1mg/L and 0.05mg/L can generate poisoning effect on cercaria after 12h, 24h, 48h and 72h, the mortality rate is stable, and the anti-miracidity effect is influenced by the concentration of niclosamide. The cercariae killing effect of the externally released medicine is almost 100% for the concentration above 0.5, but the collagen group and the double component can kill the cercariae faster and more efficiently than the gelatin group for the low concentration of the niclosamide of 0.1 mg/L.

TABLE 4 influence of hydrogel release system on the mortality of Schistosoma japonicum cercaria

In the table, "0 (gelatin)" means a one-component gelatin hydrogel having a niclosamide content of 0; "0 (single component)" means a single component collagen hydrogel with niclosamide content of 0; "0 (bi-component)" means a bi-component collagen gelatin hydrogel with niclosamide content of 0; other packet meanings are interpreted with reference to the rule.

Experimental example 5 Effect test for anti-cercaria infection of protein hydrogel containing niclosamide drug

1. Experimental method

Randomly dividing Balb/c mice into 7 groups, namely a pure gelatin group, a pure collagen group, a collagen drug group, a gelatin drug group, a collagen gelatin drug group, an anti-cercaria frost protection group and an infection group; each set of 5 was parallel. All mice were unhaired on their abdomens (1.5 cm. times.1.5 cm), and each group of mice was tightly attached to the abdomen of the unhaired mice for 20min with a slide glass containing water for killing schistosoma japonicum cercaria to infect 35 schistosoma japonicum cercaria; the infection group is coated with normal saline in advance; other groups of mice were pre-smeared with equal amounts of the following samples on the dehaired abdomens, wherein the pure gelatin group was smeared with the comparative example 6 sample; smearing the pure collagen group on the sample of the comparative example 10; smearing the sample of the comparative example 1 on the collagen drug group; coating the gelatin drug group on the sample of the comparative example 2; smearing the sample of example 1 with collagen gelatin drug group; smearing larva-protecting cream on the positive control group; the amount of the smeared sample in each group is 0.2 ml; after 0.5d, 1d, 3d, respectively, each mouse was infected with 35 cercaria in the same way. Observing the cercaria infection resisting conditions of the mice at 0.5d, 1d and 3d after the abdomen skin is smeared with niclosamide-containing hydrogel.

2. Results of the experiment

The experimental results are shown in table 5, and the results show that the average insect reduction rate of 0.5d, 1d and 3d of the mice in the pure gelatin group is 31.94%, 12.67% and 6.21%, and the average egg reduction rate is 38.51%, 10.67% and 5.21%; the average insect reduction rate of 0.5d, 1d and 3d of the pure collagen group mice is 29.19 percent, 9.67 percent and 3.67 percent; the egg reduction rate is 26.67%, 5.67% and 2.34%; the average insect reduction rate of the gelatin drug group mice at 0.5d, 1d and 3d is 80.56%, 62.63% and 51.18%, and the egg reduction rate is 83.00%, 62.39% and 43.61%; the average insect reduction rate of 0.5d, 1d and 3d of the collagen drug group mice is 62.50%, 52.67% and 31.21%, and the egg reduction rate is 73.92%, 62.27% and 43.11%; the average insect reduction rate of 0.5d, 1d and 3d of the collagen gelatin drug group mice is 85.25%, 72.17% and 65.53%, and the egg reduction rate is 87.57%, 75.42% and 68.83%. The average reduction rates of 0.5d, 1d and 3d of the anti-larva frost protection group serving as a positive reference can respectively reach 100%, 96.17% and 88.13%, and the egg reduction rates can reach 99.67%, 95.42% and 90.83%. The experimental result shows that the dual-component medicinal hydrogel has a good cercaria infection resisting effect, the parasite reduction rate can reach more than 60% after the hydrogel is smeared for 3 days, and the hydrogel is a good supplement of the cercaria-preventing cream.

TABLE 5 niclosamide protein-containing hydrogel anti-cercaria infection control test

Experimental example 6 medicinal praziquantel collagen hydrogel injection for testing the effect of schistosome infection treatment

1. Experimental methods

Randomly dividing Balb/c mice into 6 groups, which are respectively a pure gelatin injection group, a pure collagen injection group, a gelatin drug injection group, a collagen gelatin drug injection group and a praziquantel administration group，Each set of 5 was parallel. All mice were infected with 35 cercaria in the abdomen (1.5 cm. times.1.5 cm) with hair removed, and 30 days after infection, the pure gelatin injection group injected subcutaneously with the sample of comparative example 16 without praziquantel; the pure collagen injection group injected the comparative example 17 sample; gelatin drug injection group injection comparative example sample 14; the collagen drug injection group injected comparative example sample 15; collagen gelatin drug injection group injection example 7; the injection amount of each group is consistent with that of a collagen gelatin drug injection group, the final concentration of the praziquantel is ensured to be 300mg/kg, and a praziquantel administration group uses 300mg/kg of praziquantel to perfuse a stomach of a mouse. Gelatin injection group and pure collagen injection group are used as positive reference, and praziquantel administration group is used as negative reference.

42 days after infection, the mice were sacrificed by dislocation of cervical vertebrae, dissected, cut through mesentery and portal vein, counted to number of adults, and calculated to reduce the number of insects (control component number of insects-experimental component number of insects)/control component number of insects. Weighing a small amount of liver, adding 10 times of 10% NaOH solution by weight, grinding, taking 50 mu l of homogenate by using a trace liquid taking device, counting eggs under a mirror, and calculating the average egg number per 5mg of liver and egg reduction rate by taking the difference value of the egg number of the control group in the liver and the egg number of the experiment group in the calculation mode as the percentage of the egg number of the control group in the liver. Statistical analysis was performed on each set of data using SPSS12.0 software.

2. Results of the experiment

The experimental results are shown in table 6, and the experimental data show that the pest reduction rate and the egg reduction rate of the mice in the pure gelatin injection group and the pure collagen injection group are both 0%; the insect reduction rate of the gelatin drug injection group mice is 83.87 percent, and the egg reduction rate is 90.04 percent; the insect reduction rate of the collagen drug injection group mice is 79.86 percent, and the egg reduction rate is 89.70 percent; the insect reduction rate of the collagen gelatin drug injection group mice is 89.69%, and the egg reduction rate reaches 92.11%. The gavage group as a negative reference has a pest reduction rate of 100% and an egg reduction rate of 96.47%. Therefore, the collagen and gelatin bi-component medicinal hydrogel has better effect of treating schistosome infection.

TABLE 6 egg and insect reduction rates for each group of drugs

And (4) conclusion: the composite collagen hydrogel (bi-component hydrogel) has good mechanical strength and biocompatibility; in addition, the composite collagen hydrogel has larger drug loading capacity, the release time can reach 20 days, and the release rate is kept about 80%; the composite collagen hydrogel has good therapeutic effect on cercaria infection and schistosome infection, and can be used as a sustained release agent for preventing and treating schistosomiasis.

The above embodiments are preferred embodiments of the present invention, but the present invention is not limited to the above embodiments, and any other changes, modifications, substitutions, combinations, and simplifications which do not depart from the spirit and principle of the present invention should be construed as equivalents thereof, and all such changes, modifications, substitutions, combinations, and simplifications are intended to be included in the scope of the present invention.

Sequence listing

<110> Jiangsu province schistosomiasis prevention and treatment institute

<120> composite collagen hydrogel and preparation method and application thereof

<160> 1

<170> SIPOSequenceListing 1.0

<210> 1

<211> 319

<212> PRT

<213> Artificial Sequence (Artificial Sequence)

<400> 1

Cys Ala Asp Glu Gln Glu Glu Lys Ala Lys Val Arg Thr Glu Leu Ile

1 5 10 15

Gln Glu Leu Ala Gln Gly Leu Gly Gly Ile Glu Lys Lys Asn Phe Pro

20 25 30

Thr Leu Gly Asp Glu Asp Leu Asp His Thr Tyr Met Thr Lys Leu Leu

35 40 45

Thr Tyr Leu Gln Glu Arg Glu Gln Ala Glu Asn Ser Trp Arg Lys Arg

50 55 60

Leu Leu Lys Gly Ile Gln Asp His Ala Leu Asp Leu Val Pro Arg Gly

65 70 75 80

Ser Gly Gln Asp Gly Arg Asn Gly Glu Arg Gly Glu Gln Gly Pro Thr

85 90 95

Gly Pro Thr Gly Pro Ala Gly Pro Arg Gly Leu Gln Gly Leu Gln Gly

100 105 110

Leu Gln Gly Glu Arg Gly Glu Gln Gly Pro Thr Gly Pro Ala Gly Pro

115 120 125

Arg Gly Leu Gln Gly Glu Arg Gly Glu Gln Gly Pro Thr Gly Leu Ala

130 135 140

Gly Lys Ala Gly Glu Ala Gly Ala Lys Gly Glu Thr Gly Pro Cys Gly

145 150 155 160

Pro Gln Gly Pro Arg Gly Glu Gln Gly Pro Gln Gly Leu Pro Gly Lys

165 170 175

Asp Gly Glu Ala Gly Ala Gln Gly Pro Ala Gly Pro Met Gly Phe Pro

180 185 190

Gly Glu Arg Gly Glu Lys Gly Glu Pro Gly Cys Gln Gly Ala Lys Gly

195 200 205

Asp Arg Gly Glu Thr Gly Pro Val Gly Pro Arg Gly Glu Arg Gly Glu

210 215 220

Ala Gly Pro Ala Gly Lys Asp Gly Glu Arg Gly Pro Cys Gly Pro Ala

225 230 235 240

Gly Lys Asp Gly Gln Asn Gly Gln Asp Gly Leu Pro Gly Lys Asp Gly

245 250 255

Lys Asp Gly Gln Asn Gly Lys Asp Gly Leu Pro Gly Lys Asp Gly Lys

260 265 270

Asp Gly Gln Asn Gly Lys Asp Gly Leu Pro Gly Lys Asp Gly Lys Asp

275 280 285

Gly Gln Asp Gly Lys Asp Gly Leu Pro Gly Lys Asp Gly Lys Asp Gly

290 295 300

Leu Pro Gly Lys Asp Gly Lys Asp Gly Gln Pro Gly Lys Pro Cys

305 310 315

Claims

1. A composite collagen hydrogel is characterized by comprising an active component and a gel-forming component, wherein the composite collagen hydrogel is formed by converting the gel-forming component into gel through an oxidizing agent; the active component comprises niclosamide or praziquantel, before the active component is converted into gel, the mass volume concentration of the recombinant collagen in the gelling component is 20-100 g/L, the mass volume concentration of the gelatin is 10-100 g/L, and the amino acid sequence of the recombinant collagen is SEQ ID No. 1.

2. The composite collagen hydrogel according to claim 1, wherein when the active ingredient comprises niclosamide, the mass volume concentration of niclosamide in the composite collagen hydrogel is 0.1-10 mg/L.

3. The composite collagen hydrogel according to claim 1, wherein when the active ingredient comprises praziquantel, the mass volume concentration of praziquantel in the composite collagen hydrogel is 10-200 mg/L.

4. The composite collagen hydrogel according to claim 1, wherein said oxidizing agent is H ₂ O ₂ 。

5. The method for preparing the composite collagen hydrogel according to any one of claims 1 to 4, comprising the steps of:

6. The preparation method according to claim 5, wherein in S1, the temperature of the mixed solution system is 40-90 ℃.

7. The preparation method according to claim 5, wherein in the S2, the cooling and standing reaction is carried out for at least 7 days at 0-8 ℃.

8. According to claimThe preparation method of claim 5, wherein the oxidant in S2 is H with a mass volume concentration of 0.5-5 g/L ₂ O ₂ 。

9. The use of the composite collagen hydrogel according to any one of claims 1 to 4 in the preparation of a medicament for preventing and/or treating schistosomiasis infection.

10. The use according to claim 9, wherein the medicament is in the form of a spread or an injection.